Why Shared Core Facilities Can Save Biotech Startups Millions in Capital Costs

It takes much more than scientific expertise to transform a promising biotech concept into a commercially viable product. Even at an early stage, startups may need access to resources like advanced laboratory equipment, highly specialised technical capabilities, or tightly controlled research environments—all of which can become sources of substantial financial pressure.

This challenge has encouraged a shift toward more accessible research infrastructure in many biotech ecosystems around the world. In Singapore, for instance, continued investment in biomedical sciences and research facilities has helped support a collaborative innovation environment where startups, researchers, and private companies can work more efficiently through shared resources and technical infrastructure. Initiatives such as A*START Central were established in part to support biotech and medtech startups that require access to expensive laboratory infrastructure and specialised facilities, illustrating how shared resources can help lower barriers to innovation.

Although shared core facilities like life sciences incubators are often associated with convenience and collaboration, their financial impact may be even more significant for early-stage biotech companies. Instead of committing substantial capital towards building fully independent laboratory operations, startups can use shared facilities to reduce costs while still accessing the tools and environments needed for meaningful scientific progress. Here’s how they help new organisations preserve funding for the areas that most directly influence long-term growth:

1) Avoiding Major Upfront Equipment Purchases

Many biotech founders quickly discover that a single piece of laboratory equipment can consume a sizeable portion of an early funding round. Systems used for sequencing, imaging, analytical testing, or cell analysis often come with exceptionally high purchase prices, particularly when paired with installation requirements, software packages, and ongoing servicing agreements. For startups still refining their products or validating research outcomes, making these large purchases too early can significantly reduce the capital available for core activities like product development and clinical preparation.

Shared facilities help reduce this pressure by giving companies access to advanced instruments without requiring full ownership. Startups can instead use shared-access or usage-based models that allow them to pay only for the resources they currently need. This approach creates more financial flexibility during uncertain growth periods and prevents businesses from overcommitting their limited funding.

2) Reducing Laboratory Infrastructure and Maintenance Costs

The cost of scientific equipment is just the beginning when it comes to the expenses biotech startups can expect. Many forms of research require carefully controlled laboratory conditions, specialised ventilation systems, purified water supplies, backup power infrastructure, and strict environmental monitoring. It can become extremely expensive to maintain these environments independently, especially for startups operating with small teams and limited administrative support.

In contrast, operational costs at shared facilities are distributed across multiple organisations rather than carried by a single company. In many cases, startups gain access to professionally maintained research environments that already meet industry and compliance standards, removing the need to build and manage these systems internally.

3) Limiting Staffing and Technical Support Expenses

Biotech organisations need more than familiarity with scientific processes to successfully run sophisticated laboratory systems. Many advanced instruments need regular calibration, technical troubleshooting, compliance oversight, and specialised operational knowledge to function properly and produce reliable results. For smaller biotech companies, assembling a full in-house team capable of handling these responsibilities can quickly increase payroll costs and place additional strain on already limited resources.

The best shared core facilities will already employ trained technical personnel who oversee equipment management and day-to-day operational support. Startups thus gain access to experienced staff without requiring them to recruit large technical teams independently. In addition to reducing staffing expenses, the arrangement can also shorten onboarding times for new systems and help research teams avoid costly disruptions caused by equipment misuse or maintenance delays.

4) Creating More Flexibility during Early Growth Stages

Very few biotech startups follow a perfectly predictable growth path. The company’s research priorities may evolve as new findings emerge, for instance. Investor expectations might shift or regulatory realities become clearer. An organisation that initially focuses on one development pathway may eventually pivot towards a different application and then require entirely different operational needs. Under these conditions, investing heavily in permanent laboratory infrastructure too early can create long-term financial inefficiencies.

Startups that use shared facilities can take advantage of a more adaptable operating model that allows them to scale resources according to current requirements instead of future assumptions. Companies can increase or reduce laboratory usage, equipment access, technical support, and other resources depending on the stage of development they are in. The innate flexibility of this setup helps startups avoid tying large amounts of capital to infrastructure that may later become underused or unsuitable as the business evolves.

Promising scientific ideas do not always come from the largest organisations with the deepest pockets. As shared research environments become more common, smaller biotech companies may gain greater opportunities to experiment, develop, and compete in spaces that were once financially inaccessible. In the long run, shifts in this direction may help create a more equitable biotech industry where innovation is shaped by the strength of an organisation’s ideas first and foremost.